Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG CMEK162X2109

Title
A Phase IB Open-Label, Multi-Center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYl719 in Adult Patients with Selected Advanced Solid Tumors
Principal Investigator
Young Kwang Chae
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG CMEK162X2109
Purpose
The main purpose of this study is to see what effect, good and/or bad, MEK162 and BYL719 given together has on certain advanced solid tumors.
Overview
This is a phase 1 study which means the investigational drugs (not yet approved by the Food and Drug Administration [FDA]for use in treating this certain disease)have shown promise in animal testing, but have not yet been given together to humans. MEK162 works by blocking (inside the cell) a pathway that is thought to play a part in tumor cell and new blood vessel growth (which supplies blood and oxygen to the tumor). Phosphatidylinositol 3’- kinase (P13K)is a type of enzyme (protein)that is involved in tumor cell growth and multiplication. In many cancers the P13K pathway is always active. BYL719 is new type of drug that works by blocking the P13K pathway. Laboratory studies have shown that the combination of these 2 drugs can lessen tumor growth.
Eligibility
Some of the eligibility criteria include:
  • Participants must be 18 years of age or older.
  • Participants must have a certain type of advanced solid tumor. Contact the study team for more detailed information regarding this.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Both BYL719 and MEK162 are taken orally (by mouth). There are different treatment combinations of these drugs. The study doctor will tell you what amount of BYL719 and MEK162 you will take. All participants will receive treatments in cycles. Each cycle is 28 days. Participants will continue treatment until their study doctor thinks it is in their best interest to stop.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Young Kwang Chae

last updated: 31-Oct-14 01:33 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.